Difference between revisions of "Part:BBa K1202001"

Latest revision as of 22:48, 4 October 2013

C215 (Anti EpCAM)

This is the primary section of NanoFactory design. This part is one of the active domains of anti-EpCAM (Epithelial Cell Adhesion Molecule) antibody. We use this part in our NanoFactory system as a binding zone to EpCAM antigen.

Epithelial Cell Adhesion Molecule (EpCAM) is a outer-cell antigen whose expression is elevated in some cancer types such as colon and breast. This difference makes this antigen a prospective cancer marker and it is planned to be used as an detection technique in immunochemistry for the grading and determining the aggressiveness of tumor.

Anti-EpCAM antibody has three binding domains for EpCAM antigen, each of them have different binding affinity.(REF) During our researches, we determined that the best choice would be C215 binding domain with the greatest binding affinity. This would allow us bind EpCAM antigen specifically and more efficiently.

With the help of effective binding of C215, we hope to conduct accumulation of our NanoFactories on cancer cells, which hopefully ends up with amassing AI-2 units in the media and bacteria. AI-2 accumulation will start the production of cancer killing peptides.

Sequence and Features

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
COMPATIBLE WITH RFC[21]
23
COMPATIBLE WITH RFC[23]
25
COMPATIBLE WITH RFC[25]
1000
COMPATIBLE WITH RFC[1000]

@@ Line 1: / Line 1: @@
 __NOTOC__
 <partinfo>BBa_K1202001 short</partinfo>
-C215 detects and binds EpCAM antigen on the cells.
+This is the primary section of NanoFactory design. This part is one of the active domains of anti-EpCAM (Epithelial Cell Adhesion Molecule) antibody. We use this part in our NanoFactory system as a binding zone to EpCAM antigen.
+Epithelial Cell Adhesion Molecule (EpCAM) is a outer-cell antigen whose expression is elevated in some cancer types such as colon and breast. This difference makes this antigen a prospective cancer marker and it is planned to be used as an detection technique in immunochemistry for the grading and determining the aggressiveness of tumor.
+Anti-EpCAM antibody has three binding domains for EpCAM antigen, each of them have different binding affinity.(REF) During our researches, we determined that the best choice would be C215 binding domain with the greatest binding affinity. This would allow us bind EpCAM antigen specifically and more efficiently.
+With the help of effective binding of C215, we hope to conduct accumulation of our NanoFactories on cancer cells, which hopefully ends up with amassing AI-2 units in the media and bacteria. AI-2 accumulation will start the production of cancer killing peptides.
 <!-- Add more about the biology of this part here